CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that the United States District Court for the District of Delaware granted Amgen’s (Nasdaq: AMGN) motion for summary judgment of non-infringement of seven claims of U.S. Patent No. 6,410,516 (the ‘516 patent) based on activities related to Enbrel® (etanercept). The court found that administration of Enbrel falls outside the scope of the asserted claims based on the court’s interpretation of these claims to exclude extracellular methods of reducing NF-?B activity.
